AlphAIAlphAI — Financial news for AI agents
newsfilecorp.comSEP 102 min read$XERS

medmix' Drug Delivery ("Haselmeier") to Support the Development of Xeris Pharmaceuticals' XP-8121 with D-Flex(TM) Pen Injector

medmix' Drug Delivery (Haselmeier) partners with Xeris Pharmaceuticals to develop XP-8121, a once-weekly hypothyroidism treatment. The D-Flex™ pen injector, with high dose accuracy, will be used for precise delivery of the drug. Both companies emphasize the importance of accurate dosing for narrow therapeutic index drugs. medmix' shares are traded on the SIX Swiss Exchange (SIX: MEDX).

Original reporting
newsfilecorp.com
Published Sep 10, 2026, 7:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 10:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
medmix' Drug Delivery ("Haselmeier") to Support the Development of Xeris Pharmaceuticals' XP-8121 with D-Flex(TM) Pen Injector — source image
Source · newsfilecorp.com
Decision brief

The 30-second read

$XERSBullishLow
01

Why it matters

The collaboration could accelerate XP-8121 development and expand medmix's US market footprint.

02

Market read

A new device partnership that may influence niche biotech and medtech stocks.

03

What to watch

Regulatory pathway for combination device‑drug products may introduce additional hurdles.

Relevance 6/10Novelty 6/10Timing: today

Background

medmix (SIX: MEDX) is a Swiss device maker; Xeris Pharmaceuticals (NASDAQ: XERS) develops thyroid therapies.

Company-level read

Ticker impact

$XERSBullishMedium confidence
Context

Xeris selected medmix's D-Flex platform for its investigational levothyroxine product XP-8121.

Expected impact

moderate upside if trial data confirm dosing benefits

Evidence & confidence

New partnership disclosed; relevance tied to upcoming clinical milestones.

Market effects

Sector

Highlights growing demand for precision drug‑delivery devices in endocrine therapies.

Regional

May benefit Swiss device manufacturers and US biotech investors.

Global

Limited to niche NTI drug segment; no broad market shift expected.

Counterpoint

What could challenge this read

If XP-8121 fails later-stage trials, the partnership could add cost without revenue.

Key entities

  • company
    medmix

    Swiss precision drug‑delivery device manufacturer.

  • company
    Xeris Pharmaceuticals

    US biotech developing levothyroxine therapy XP-8121.

Read at source← All news

Related articles

SEP 30
$IOVAMedAI 8/10

Biotech Stocks At 52-Week Highs - IOVA +31%, XERS, GRAL, ABCL, SGHT

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.

rttnews.com2 min
SEP 29
$XERSMed

Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports

Lundbeck (LON:0ND5) has shown interest in acquiring Xeris Pharmaceuticals (NASDAQ:XERS), according to Bloomberg. Xeris, focused on endocrine and rare disease therapies, stated it is not for sale. Lundbeck, specializing in neurological and psychiatric conditions, may expand into rare endocrine disorders through this potential deal. Discussions are preliminary, and no formal offer has been made.

investing.com2 min
AUG 13
$XERSMedAI 8/10

Xeris (XERS) Q2 2026 Earnings Call Transcript

Xeris (XERS) Q2 2026 earnings call said it retired its convertible notes, eliminating nearly $3 million in annual interest expense. The company raised full-year 2026 total revenue guidance to $385 million to $390 million. Q2 net product revenue was $91 million (+34% YoY) and total revenue $92.1 million (+29%). Recorlev net revenue was $56.8 million (+81% YoY), Gvoke about $23 million, and Keveyis nearly $12 million. It also reported new U.S. patent allowances for Keveyis and XP-8121.

yahoo.com7 min
AUG 6
$XERSMed

XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Xeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Total revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue increased 81% year-over-year to approximately $57 million Tightens full

SEC EDGAR 8-K6 min